Inhibition of indoleamine-2,3-dioxygenase 1 (IDO1), a key enzyme regulating tryptophan catabolism to the AhR ligand (AhRL) kynurenine, has been proposed to abrogate tumor intrinsic malignant signaling and enhance anti-tumor immunity [15,16]. Here, IDO1 is linked to neoplasm.